Decades Of Ban, Zero Science — Why

For decades, Washington’s war on marijuana did not stop Americans from using it — it mainly stopped scientists from studying it.

Story Snapshot

Federal bans failed to curb marijuana use but choked off serious medical research.
Trump’s order and new Justice Department moves push marijuana toward Schedule III to unlock research.
Drug Enforcement Administration hearings still favor prohibition voices and sideline reform advocates.
Rescheduling would ease tax burdens and research rules but would not legalize recreational pot.

How Prohibition Fueled Use But Blocked Knowledge

Federal officials banned marijuana more than 50 years ago under the Controlled Substances Act, putting it in Schedule I with heroin and lysergic acid diethylamide and claiming it had no accepted medical use.^[3] That label did not stop people from using it. Surveys show tens of millions of Americans have tried marijuana, and about one in six used it in the past month, even while it remained illegal at the federal level.^[6] What the ban did stop was broad medical study, creating a gap in hard data on real health risks and benefits.

Researchers who wanted to study marijuana had to clear the highest legal hurdles because Schedule I drugs face strict Drug Enforcement Administration licensing, security rules, and sourcing limits.^[3] For years, scientists could only get research cannabis through a federal monopoly supply, often with weak potency and strains unlike what patients and consumers actually use.^[3] A major national science review found that these barriers left doctors, patients, and lawmakers without solid evidence when making decisions about pain care, cancer support, or mental health.^[3] The result was policy built on fear and politics instead of facts.

Trump’s Push Toward Schedule III And Real Medical Research

The turning point came in 2023 when the Department of Health and Human Services recommended moving marijuana from Schedule I to Schedule III after a formal scientific and medical review.^[1] Health and Human Services pointed to credible support for marijuana’s use to treat pain, nausea, and appetite loss, undercutting the old claim that the plant has “no accepted medical use.”^[1] In 2024, the Drug Enforcement Administration proposed a rule to follow that advice and reschedule marijuana, opening the door to a major shift in federal policy.^[1]

President Trump then stepped in to break the bureaucratic logjam. His executive order directed the Attorney General to speed up rescheduling and expand federal research on medical marijuana and hemp-based cannabinoids.^[16] Acting on that direction, the Justice Department announced an order placing Food and Drug Administration–approved marijuana products and state-regulated medical marijuana into Schedule III right away.^[21] The department said this move was meant to let doctors and scientists study safety and effectiveness more freely so patients could get better care and more reliable information.^[21]

What Schedule III Really Changes — And What It Does Not

Moving marijuana to Schedule III would not legalize recreational use or make joints and edibles available over the counter at your local gas station.^[12] Marijuana would still be a controlled substance, and interstate commercial sales would stay illegal under federal law.^[17] States could keep enforcing their own rules, and employers would still be able to demand drug-free workplaces and test workers when safety is at stake.^[18] Rescheduling is an important change, but it does not erase all federal power over the cannabis market.

Rescheduling does matter for two key reasons that should interest conservative taxpayers and small business owners. First, research rules for Schedule III drugs are less burdensome than for Schedule I. Universities and clinics can run more double-blind and placebo-controlled trials without years of delay.^[9] Second, rescheduling would lift the weight of Section 280E of the tax code, which now blocks legal marijuana businesses from taking normal deductions because the plant is listed in Schedule I.^[6] Moving marijuana to Schedule III would free state-licensed medical operators from that extra tax punishment, allowing more transparent business and jobs rather than pushing activity into the black market.

DEA Hearings, Prohibition Holdouts, And The Battle Over Evidence

Even with Trump’s order and the Justice Department’s new stance, the Drug Enforcement Administration is not eager to let go of old prohibition habits. For the June 29, 2026 rescheduling hearing, the agency denied participation requests from major reform groups like the National Organization for the Reform of Marijuana Laws and other cannabis policy advocates.^[4] Instead, it chose only organizations that want to keep marijuana in Schedule I, slanting the hearing record toward continued criminalization.^[4] This setup keeps the national debate stuck in a past that many voters no longer support.

"A Drug Enforcement Administration (DEA) judge has issued an order laying out the schedule for a hearing on the Trump administration’s move to reschedule cannabis that is set to start next week."#Marijuana #Cannabis #DEA #Rescheduling #Hearing #Schedule https://t.co/Tvt8kd54qd

— Omni Medical Services (@omnimedicalmmj) June 25, 2026

Critics say this approach repeats a “regulatory catch‑22” that has plagued marijuana policy for decades. A report from the Multidisciplinary Association for Psychedelic Studies and the Drug Policy Alliance describes how the Drug Enforcement Administration has long claimed there is not enough evidence to loosen marijuana’s status while also blocking the very research that would produce that evidence.^[14] That tactic kept cannabis tied to heroin and lysergic acid diethylamide in Schedule I and fueled suffering for patients who might have been helped by low‑cost, low‑risk marijuana treatments.^[14] Trump’s push toward Schedule III is aimed at breaking that loop, but agency resistance shows the fight is far from over.

Why Conservative Voters Should Care About Getting The Science Right

For constitutional conservatives, the core issue is not promoting drug use. It is demanding honest science, sensible limits, and smaller, smarter government. Schedule I status has failed to stop widespread marijuana use, yet it has blocked free-market innovation and serious studies that could guide responsible rules.^[3] Rescheduling to Schedule III, with strict medical controls, allows research and patient care to move forward while keeping clear boundaries against reckless recreational legalization at the federal level.^[1] That balance respects state choice, protects families, and starts to roll back a failed, expensive chapter of the drug war.